EVMN Q2 2025 Earnings — Evommune, Inc. Revenue & Financial Results | Market Cap Arena

EVMNEvommune, Inc.

$319M

Q2 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

-$375,000

Operating Income

-$23M

Net Income

-$14M

EPS (Diluted)

$-0.45

QoQ Revenue Growth

-100.0%

Cash Flow

Operating Cash Flow

-$26M

Free Cash Flow

-$26M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$96M

Total Liabilities

$267M

Stockholders' Equity

-$171M

Cash & Equivalents

$62M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	-$375,000	-$325,000	-15.4%
Operating Income	-$23M	-$28M	+18.7%
Net Income	-$14M	-$27M	+50.5%